Latest Antibody Stories

The mere thought of an identification error sends a chill down the spine of any mushroom lover: The death cap mushroom (Amanita phalloides), which resembles the common white button mushroom, contains one of the most deadly poisons found in nature, α-amanitin. This substance kills any cell without exception, whether it be healthy or cancerous. At the German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) and the National Center for Tumor Diseases Heidelberg, immunologist Dr....

The characterisation of a rare immune cell’s involvement in antibody production and ability to ‘remember’ infectious agents could help to improve vaccination and lead to new treatments for immune disorders, say researchers from the Walter and Eliza Hall Institute. The cells, called T follicular helper cells, represent less than half of one per cent of all immune cells, but play a critical role in antibody production and developing long-lasting immunity. However, the cells are also...

Creating a radioactive antibody fragment may allow scientists to identify fat and debris deposits in artery walls that are most likely to rupture and cause heart attacks. Of the more than 17 million annual cardiovascular deaths worldwide, most result from ruptured plaque. "The detection of vulnerable coronary plaques is a major clinical challenge because it would allow preventive patient management prior to a heart attack," said Alexis Broisat, Ph.D., the study's lead author and a...

Innovative TAU tool for immune system activation could lead to better drug delivery Developing a drug or vaccine requires a delicate balancing act with the immune system. On one hand, medications need to escape detection by the immune system in order to perform their function. But vaccinations — de-activated versions of a disease or virus — need to do the reverse. They prompt the immune system to create protective antibodies. But scientists are still stumped by how the immune system...

CHARLOTTE, N.C., March 26, 2012 /PRNewswire/ -- CSL Behring has announced that the first patient has been enrolled in the PATH study, an international clinical trial designed to evaluate the efficacy, safety, and tolerability of two different doses of subcutaneous immunoglobulin (SCIg), compared with placebo, in maintenance treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). In PATH (Polyneuropathy And Treatment with Hizentra), patients stabilized on intravenous...

ROCKVILLE, Md., March 20, 2012 /PRNewswire/ -- OriGene Technologies today announced the release of a new line of ultra specific and extensively validated monoclonal antibodies under the UltraMAB(TM) brand. UltraMAB Antibodies are a collection of monoclonal antibodies which are exclusively developed by OriGene for IHC applications and are the industry's only antibody products available on the market that have been validated with the Company's breakthrough 10K High Density Protein...

ROTTERDAM, the Netherlands and GHENT, Belgium, March 19, 2012 /PRNewswire/ -- ADDS A SECOND PROPRIETARY TECHNOLOGY TO LEVERAGE THE POWER OF THE SIMPLE ANTIBODY(TM) PLATFORM arGEN-X announces today the launch of NHance(TM), its latest cutting-edge technology enabling the creation of truly differentiated human antibody therapeutics. NHance(TM) technology significantly prolongs the circulation time of therapeutic antibodies in the human body by engineering of the...

ROTTERDAM, the Netherlands and GHENT, Belgium, March 19, 2012 /PRNewswire/ -- arGEN-X, a biopharmaceutical company focused on the discovery and development of human monoclonal antibodies from its proprietary SIMPLE Antibody(TM) platform, announces today that it has strengthened its management team with two key hires. Alain Thibault, MD joins the Company as Chief Medical Officer, while Jacobus (Koos) Rasser, PhD, JD will serve as IP Counsel. Dr. Alain Thibault has gained...

Antibodies, once touted as the "magic bullets" of cancer care, are now fulfilling that promise and more advances are on the way, say cancer researchers at the Georgetown Lombardi Comprehensive Cancer Center In a review article posted online March 16 in Cell, the researchers say that refinements and modifications of monoclonal antibody drugs -- several of which have already revolutionized the care of breast and colon cancer --are now being tested in most tumor types. These modifications...

SAN DIEGO, March 15, 2012 /PRNewswire/ -- AnaptysBio, Inc., a privately held therapeutic antibody company, today announced the addition of David L. Lacey, M.D. and Michael Gallatin, Ph.D. to the company's Therapeutic Advisory Board (TAB). Drs. Lacey and Gallatin will join two founding members of AnaptysBio's TAB, Jan de Vries, Ph.D. and Nicholas B. Lydon, Ph.D. (Logo: http://photos.prnewswire.com/prnh/20111205/SF16052LOGO) AnaptysBio's TAB is constituted to oversee the...